Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses - Wikidata - wikimedia - TriplyDB

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

http://www.wikidata.org/entity/Q30377017

about

Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines Recent advances of vaccine adjuvants for infectious diseases Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.Prime-boost immunization using a DNA vaccine delivered by attenuated Salmonella enterica serovar typhimurium and a killed vaccine completely protects chickens from H5N1 highly pathogenic avian influenza virus.Collectivism/individualism and its relationship to behavioral and physiological immunity.HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.Rotavirus enterotoxin NSP4 has mucosal adjuvant properties.Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3.Optimizing efficacy of mucosal vaccines.

P2860

Q27013568-932E68D8-0FE9-4666-8521-14588E4323BE Q28083679-FBFF1F0A-D882-43CB-A56A-3C298F84362C Q30403760-8CFC2244-EA32-441D-A8F8-A971E21C4EFC Q33768698-7FD4C7FB-BCD9-49AD-A694-6DDD2FEB7004 Q35136165-55E2740A-2FF9-4242-B7ED-3E1C59992D0F Q35883997-0BB5EECE-D87D-4B4B-9A18-525052C11200 Q36873521-BB008AF4-B5DF-419D-8670-D33659661FAA Q37342874-F84EE7F7-DD14-4DA2-91FC-57CCCAF78971 Q38059754-738D0EAD-9840-4FA4-A5B3-357051253EEF

P2860

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

http://www.wikidata.org/entity/Q30377017

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

@ast

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

@en

type

label

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

@ast

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

@en

prefLabel

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

@ast

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

@en

P1433

Q30377017-2F9E83C7-9621-4F7B-BFAF-6B53F2E8D5D1

P1476

Q30377017-F9740EC1-4FF6-40F2-83B0-11B09F4D39CF

P2093

Q30377017-605AB06D-A078-4A1C-A5F6-5D6399683B45

Q30377017-6AD0D9B0-9A1F-41C4-9BBD-2B1C0F855C5B

Q30377017-70ADE079-FC05-4060-B159-1BB139FBA93E

Q30377017-C28C5940-D85B-48E3-94BC-F07802AF1593

Q30377017-D1B989D0-2FB8-4282-9FDE-96F6F6B5874B

P2860

Q30377017-04E7990B-D3AC-4B48-8789-12F2D303ADE3

Q30377017-0CB26281-459C-4782-B258-074EBC8D59D1

Q30377017-0E546525-CBEF-4BC3-A5B1-851551CC3CEF

Q30377017-17817062-FC4D-4750-87BC-EE118A977748

Q30377017-20DE3FCE-4C65-4D19-8E8B-BA3CEDF25C93

Q30377017-2689AF40-BC17-4F5F-A251-1DE2DB29A222

Q30377017-28780619-8958-4F46-9D54-228C568D4251

Q30377017-36DA3116-E29E-47EE-BE2D-DC8852691AC0

Q30377017-37D8AE87-12E9-46FA-9C13-5DA32E5DC0C6

Q30377017-414DA9EA-66C0-4679-AF4F-EF9F7FB125BE

P304

Q30377017-5BF8FC52-44A7-4116-B3CD-2882DAACABD4

P31

Q30377017-68553752-3176-4E0B-98F9-0E19FA76FFFA

P356

Q30377017-66936872-E760-493C-A8D4-185892B47543

P433

Q30377017-D2FFC308-18FA-4A30-8EFA-3E093EBEC348

P478

Q30377017-47F4C891-3A31-4E49-8D9D-558375FC32C2

P577

Q30377017-60A24704-45A3-4616-AAA0-0E9D1922CA44

P5875

Q30377017-F0E7D5CD-BAB0-4AAD-ACA7-9E48012D2E47

P698

Q30377017-8481A89A-A5EE-490F-9DD5-E6E94C430798

P932

Q30377017-8E3D1995-3834-4874-831E-61079AC51150

P356

P1433

Therapeutics and Clinical Risk Management

P1476

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

@en

P2093

Akira Ainai

http://www.w3.org/2001/XMLSchema#string

Hideki Hasegawa

http://www.w3.org/2001/XMLSchema#string

Shin-Ichi Tamura

http://www.w3.org/2001/XMLSchema#string

Takeshi Ichinohe

http://www.w3.org/2001/XMLSchema#string

Takeshi Kurata

http://www.w3.org/2001/XMLSchema#string

P2860

Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets

Recognition of single-stranded RNA viruses by Toll-like receptor 7

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine

Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome

Probable person-to-person transmission of avian influenza A (H5N1)

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness

Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic.

P304

125-132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S3297

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273818850

http://www.w3.org/2001/XMLSchema#string

P698

19436601

http://www.w3.org/2001/XMLSchema#string

P932

2697507

http://www.w3.org/2001/XMLSchema#string